PARPs as Therapeutic Targets in Clinical Oncology

The 17 members of the poly (ADP-ribose) polymerase (PARP) family play critical roles in an array of normal cellular processes that include DNA repair, the stress response, chromatin dynamics, and cell death. PARP1, the most characterized of the PARPs, was linked first with single-strand DNA damage detection and repair though it has since been shown to be active in other DNA repair mechanisms. PARP inhibitors (PARPi) have become valuable agents against tumors that are compromised in homologous recombination repair (most notably those bearing mutations in BRCA1/2), with multiple PARPi drugs already approved or being tested clinically for treatment of breast, ovarian, pancreatic, lung, and other major cancers (1).

GeneTex offers an extensive catalog of well-validated antibodies for cancer research, including the new recombinant rabbit monoclonal PARP antibodies shown below. These reagents are exciting additions to our listing of products for PARP research. To learn more, please see the images below and visit our website at www.genetex.com for more details.